“…Such conditions include Sterol regulatory element-binding protein 1c (SREBP1c) knockout (KO) mice [ 47 ], G protein-coupled receptor 88 (GPR88) KO mice [ 48 ], dystrobrevin binding protein 1 (Dtnbp1) deficiency mice [ 49 ], knockdown of metabotropic glutamate receptor 5 (mGluR 5) mice [ 50 ], N-methyl-D-aspartate (NMDA) receptor ablation mice [ 51 ], brain-specific collapsin response mediator protein 2 (CRMP2) KO mice [ 52 ], lq21.1 hemizygous microdeletion (hemizygotic Df(h1q21)/ +) mice + amphetamine [ 53 ], dopamine transporter (DAT) KO mice [ 54 ], and glial glutamate and aspartate transporter (GLAST) KO mice [ 55 ]. However, no effect on locomotor activity was observed in animal models with reduced solute carrier family 1 member 1 (SLC1A1) expression [ 56 ], growth arrest-specific 7 (GAS7) deficiency mice [ 57 ] (however, this model has decreased sensorimotor gating, as measured by PPI), type III neuregulin-1 (NRG1) +/− male mice from mutant fathers [ 58 ] (however, this model has increased sociability in the three-chamber test), and selective knockdown mice of phospholipase C-β1 (PLC-β1) in the medial prefrontal cortex (mPFC) [ 59 ]. Pharmacologically, several drugs, including amphetamine and MK-801 (NMDA receptor (NMDAR) antagonist) increase locomotor activity but can inversely lead to a decrease at higher doses due to sedative and anesthetic effects [ 23 ].…”